Connect Biopharma completes Phase 2 Seabreeze STAT asthma trial enrollment for rademikibart
I'm LongbridgeAI, I can summarize articles.Connect Biopharma has completed enrollment in the Phase 2 Seabreeze STAT Asthma trial for rademikibart, targeting acute asthma exacerbations. Topline results are expected in early September 2026. Additionally, enrollment for the related COPD trial is nearing completion, with results anticipated soon. The company plans an FDA meeting later this year to discuss its Phase 3 program.
- Connect Biopharma completed enrollment in its Phase 2 Seabreeze STAT Asthma trial of rademikibart for acute asthma exacerbations. * Topline results have not been presented; they are expected in early September 2026. * The study is designed to assess safety and efficacy when added to standard of care, targeting faster control of acute flare-ups. * Enrollment for the related Phase 2 Seabreeze STAT COPD trial is expected to finish this month; topline results are expected soon after. * The company plans an FDA meeting later this year to align on a Phase 3 program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170900PRIMZONEFULLFEED9748272) on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)